Clinical and Market Analysis of NanoBEO: A Public-Worth, Innovative Therapy for Behavioral and Psychological Symptoms of Dementia (BPSD)—Emerging Evidence and Its Implications for a Health Technology Assessment (HTA) and Decision-Making in National H
NanoBEO represents a public-worth innovation in this neglected area, marking a significant advancement in the history of dementia, moving from academic research to product development.
Authors
- Maria Tiziana Corasaniti (ORCID: https://orcid.org/0000-0001-6472-0697)
- Damiana Scuteri (ORCID: https://orcid.org/0000-0001-5846-7058)
- Giacinto Bagetta (ORCID: https://orcid.org/0000-0001-8540-6218)
- Loris Pignolo (ORCID: https://orcid.org/0000-0001-9706-0779)
- Kengo Hamamura (ORCID: https://orcid.org/0000-0001-9146-8554)
- Pierluigi Nicotera (ORCID: https://orcid.org/0000-0003-1175-7466)
- Takafumi Hayashi (ORCID: https://orcid.org/0000-0003-1932-5158)
- Daniele Pierobon
- Martina Pagliaro
Institutions
- Kyushu University (JP)
- German Center for Neurodegenerative Diseases (DE)
- Magna Graecia University (IT)
- Istituto S.Anna Crotone (IT)
- University of Calabria (IT)
- Tohoku Medical and Pharmaceutical University (JP)
Publication Details
- Journal
- Pharmaceutics
- Published
- 2024-09-27
- DOI
- https://doi.org/10.3390/pharmaceutics16101253
- Citations
- 1
- Primary Topic
- Health Systems, Economic Evaluations, Quality of Life
- Type
- article
- Field-Weighted Citation Impact
- 1.13
Funders
- Ministero della Salute
- European Regional Development Fund